The Massachusetts attorney general reported Medtronic agreed to a settlement in an investigation involving the company's Infuse bone graft product, Reuters reports.
Here are six things to know:
1. Two units of Medtronic will pay $12 million to settle claims that it promoted a "deceptive marketing strategy" for its Infuse product.
2. The involved attorney generals — from Massachusetts, Oregon, California, Illinois and Washington — claimed the company boosted the product's sales via scientific literature it sponsored. The literature didn't highlight the side-effects or adverse results of Infuse.
3. Under this settlement, Medtronic must publicly release its Infuse trial data to a government website.
4. Medtronic didn't admit any wrongdoing in this case.
5. In 2012, the U.S. Senate Finance Committee discovered the company was involved in the Infuse studies' content and paid physicians $210 million to publish.
6. In addition to this lawsuit, Medtronic experienced about 6,000 actual and threatened suits regarding the company's allowance of off-label Infuse use. Medtronic reported it reached settlements for "substantially all" of these suits earlier this year.